Life-long resting CD4+ T-cells are the major long-lasting reservoir in HIV-infected individuals. The aim of our study is to analyze the dynamics of archived HIV-DNA in CD4+ T-cells subsets in individuals starting successful dolutegravir-based regimen over 48 weeks.
Participants from the prospective longitudinal DRONE study (NCT02557997) including: treatment-naïve individuals who initiated treatment with a dolutegravir-based regimen during acute (AI) or chronic (CI) infection, and treatment-experienced individuals who started a dolutegravir-based regimen while in virological success (VS) or in the aftermath of virological failure (VF), were enrolled in this substudy. Peripheral blood mononuclear cells (PBMCs) from baseline and week 48 of successful treatment were sorted in effector memory (TEM), transitional memory (TTM), central memory (TCM) and naïve (TN) CD4+ T-cells for total HIV-DNA measurements. Bayesian methods were used to estimate the posterior probability (Pr) that HIV-DNA decreased for more than 0.25 log copies/10^6 cells at week 48.
Twenty-seven participants (8, 5, 10, 4 individuals in the AI, CI, VS and VF group, respectively) were included. Patients were primarily male (88%) with a median age of 38 years (range, 20-54). At baseline, the highest contributions to the HIV-infected pool of CD4+ T-cells were observed in TTM cells in the AI group (62.8%), but in TCM cells for the CI, VS and VF groups (58.8%, 57.9%, 55.8%), respectively (Figure). After one year of dolutegravir-based regimen, TTM cells for the AI group (60.2%) and TCM cells for the CI, VS and VF groups (55.2%, 63.2% and 73.6%, respectively) still represented the main HIV reservoir. In these respective cells, a HIV-DNA decline was observed after 48 weeks of treatment in the AI group (4.00 to 3.26 log copies/10^6 TTM cells, Pr>99%), in the CI group (4.07 to 3.57 log copies/10^6 TCM cells, Pr=92%) and in the VF group (4.13 to 3.84 log copies/10^6 TCM cells, Pr=59%) but not in the VS group (4.19 to 4.12 log copies/10^6 TCM cells, Pr=8%).
HIV-DNA was mainly confined to TTM or TCM cells, when antiretroviral treatment was introduced in acute or chronic HIV infection, respectively. Forty-eight weeks of a dolutegravir-based regimen lowered the HIV-DNA load in these reservoir cells when treatment was introduced in acute infection, chronic infection or in case of virological failure but not as a switching therapy.